Hepatitis C virus (HCV) represents a significant global public health burden, and long-term infection can lead to many serious liver-related outcomes including liver cirrhosis, hepatocellular carcinoma (HCC) and liver-related mortality. With the advent of interferon-free direct acting antiviral (DAA) therapies, which have the prospect of shorter, more efficacious treatment regimens with a higher degree of tolerability, the treatment paradigm is rapidly changing in many countries around the world.
In May 2014 and January 2015, two supplements were published in the Journal of Viral Hepatitis presenting data from 32 countries on the historical epidemiology of HCV, the current disease burden and potential strategies that could be used to manage the HCV disease burden in the future [1] [2] [3] [4] [5] [6] . The countries included in those manuscripts were from multiple regions including North and South America, Europe, Asia, the Middle East, Africa and Oceania. In this supplement, data from an additional 15 countries are presented, following a similar pattern as in the previous manuscripts. These countries represent a mixture of high-and middle-income countries that hail from three geographical regions: Europe, Asia and the Middle East.
There is a wide variance in the availability of robust data in the countries represented in the analyses contained in this supplement. Expert advisory panels were convened in each country to identify the best data sources to use and review the assumptions and outputs from the model.
As could be expected given the geographical variation of the countries included in this supplement, there was considerable variability in the HCV genotype distribution (Fig. 1) , with five of the countries having less than 50% genotype 1 [Iceland, Lebanon, Pakistan, Saudi Arabia and United Arab Emirates (UAE)]. Genotype 2 was more significant in countries in Asia, including Indonesia, Japan and South Korea (range: 20-45%); genotype 3 was dominant in Iceland and Pakistan; while genotype 4 was only significant in countries in the Middle East: UAE, Lebanon and Saudi Arabia (range: 33-53%).
Differences were also pronounced when comparing estimates of HCV prevalence, diagnosis and treatment rates (Figs 2 and 3, Table 1 ). Viremic prevalence estimates for 2014 ranged from 0.2% in Iran and Lebanon to 3.9% in Pakistan. Diagnosis rates ranged from 4% in Indonesia to 83% in Iceland; however, Iceland is unique in that its geographical location and small size likely has facilitated a successful screening strategy. Estonia and Japan report the highest treatment rates of the included countries, with 2.6% of chronic HCV patients treated annually. In contrast, Indonesia has the lowest treatment rate, with <0.01% of its HCV patients receiving treatment annually, a fact made even more significant given the large size of its prevalent population. In terms of total annual treatment numbers, Pakistan currently treats a significant number of patients (85 000 per year); however, given the fact that Pakistan is estimated to have over seven million chronic HCV patients, their treatment rate is only 1.2%.
Significant variability is also clear when comparing the distribution of liver disease stages within each country (Fig. 4) . Japan has by far the 'oldest' epidemic of the countries under study, given that the majority of HCV patients (>50%) are classified with significant fibrosis (F4). How- ever, even in countries such as Iran, where >80% of chronic HCV patients are classified as having early liver disease (F0/1), the burden of advanced disease outcomes will likely increase in the coming years as the prevalent population ages and their disease progresses.
Several of the countries report a relatively high current sustained virological response (SVR) rate of >75%, including Indonesia, Slovenia and Saudi Arabia (78%, 80% and 86.8%, respectively). In these countries, introduction of new interferon-free DAA therapies at the same treatment level will only have a modest impact on overall disease burden, even more so given the low treatment rates in Indonesia and Saudi Arabia. As demonstrated through the modelling exercises described in the third manuscript included in this supplement, in order to have a large impact on the overall disease burden, countries will need to implement strategies that increase their screening, diagnosis and treatment uptake.
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